To further discover the mechanism of action of YYFZ in the treatment of CHD, GO enrichment analysis was performed using the DAVID database for the common targets obtained above (Figure 9), and a total of 162 enrichment results were obtained for biological process (BP) screening at p < 0.05, mainly involving positive regulation of protein kinase B signaling, positive regulation of smooth muscle cell proliferation, phosphatidylinositol 3-kinase signaling. This evidence concerns the gene AKT1 and coronary artery disorder.